Acadia Pharmaceuticals (ACAD) PT Lowered to $33 at Canaccord Genuity, 'would not be surprised if ACAD decides to not pursue a sNDA in NSS'
Canaccord Genuity analyst Sumant Kulkami lowered the price target on Acadia ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)